Real time electronic cell sensing systems and applications for cell-based assays
The present invention includes devices, systems, and methods for assaying cells using cell-substrate impedance monitoring. In one aspect, the invention provides cell-substrate impedance monitoring devices that comprise electrode arrays on a nonconducting substrate, in which each of the arrays has an approximately uniform electrode resistance across the entire array. In another aspect, the invention provides cellular assays that use impedance monitoring to detect changes in cell behavior or state. In some preferred aspects, the assays are designed to investigate the affects of compounds on cells, such as cytotoxicity assays.
1. A method of performing a cell-based assay, comprising:
(a) providing a cell-substrate impedance monitoring system, comprising:
(i) at least one multiple-well cell-substrate impedance measuring device, wherein at least two of the multiple wells comprise an electrode array at the bottom of the well, wherein each of said electrode arrays comprises two electrode structures and each electrode structure comprises multiple electrode elements, further wherein electrode array is individually addressed;
(ii) an impedance analyzer;
(iii) a device station comprising electronic circuitry capable of engaging said device and selecting and connecting electrode arrays within any of the multiple wells to the impedance analyzer;
(b) a software program capable of controlling the device station and performing data acquisition and data analysis from said impedance analyzer;
(c) introducing cells characterized as a having a cancer lineage into one or more wells of said device, wherein at least one of said one or more wells comprises an electrode array;
(d) culturing said cells to achieve an exponential growth phase;
(e) monitoring cell-substrate impedance of said at least one well;
(f) adding a drug suspected of being having an anti-cancer activity to said cells while in the exponential growth phase;
(g) continuing to monitor cell-substrate impedance of said at least one well; and
(h) assaying cell status, wherein cell status refers to one or more selected from the group consisting of cell attachment or adhesion on the substrate including on the electrodes, the degree of cell spreading, the attachment area of the cell, the degree of tightness of cell attachment, cell morphology, cell growth or proliferation status;
number of viable cells and/or dead cells in a well, cytoskeleton change and re-organization, and number of cells going through apoptosis and/or necrosis.
2. The method according to claim 1 , wherein cells are added to at least two wells of said device, each of which comprises an electrode array, and wherein said drug is added to the said at least two wells in different concentrations, further wherein impedance is monitored from said at least two wells.
3. The method according to claim 1 , wherein said monitoring impedance comprises monitoring impedances at three or more time points.
4. The method according to claim 3 , wherein at least three of said three or more time points are spaced at regular intervals.
5. The method according to claim 1 , wherein said cells are primary cells isolated from any species, or cells of cell lines.
6. The method according to claim 1 , wherein impedance is monitored at one frequency.
7. The method according to claim 1 , wherein impedance is monitored at multiple frequencies.
8. The method according to claim 7 , wherein impedance is monitored at multiple time points and at multiple frequencies at each of the time point.
9. The method according to claim 1 , wherein said cell-based assay is an assay selected from the group consisting of cell adhesion, cell apoptosis, cell differentiation, cell proliferation, cell survival, cytotoxicity, cell morphology detection, cell quantification, cell quality control, time-dependent cytotoxicity profiling, receptor-ligand binding, viral and bacterial toxin mediated cell pathologic changes and cell death, detection and quantification of neutralizing antibodies, specific T-cell mediated cytotoxic effect, and cell-based assay for screening and measuring ligand-receptor binding.
10. A method of performing a cell-based assay, comprising:
(a) providing a cell-substrate impedance monitoring system, comprising:
(i) at least one multiple-well cell-substrate impedance measuring device, wherein at least two of the multiple wells comprise an electrode array at the bottom of the well, wherein each of said electrode arrays comprises two electrode structures and each electrode structure comprises multiple electrode elements, further wherein electrode array is individually addressed;
(ii) an impedance analyzer;
(iii) a device station comprising electronic circuitry capable of engaging said device and selecting and connecting electrode arrays within any of the multiple wells to the impedance analyzer;
(b) a software program capable of controlling the device station and performing data acquisition and data analysis from said impedance analyzer;
(c) introducing cells characterized as a having a cancer lineage into one or more wells of said device, wherein at least one of said one or more wells comprises an electrode array;
(d) culturing said cells to achieve an exponential growth phase;
(e) monitoring cell-substrate impedance of said at least one well;
adding a drug suspected of being having an anti-cancer activity to said cells while in the exponential growth phase;
(g) continuing to monitor cell-substrate impedance of said at least one well;
(h) calculating cell index values from impedance measurements obtained before and after adding said drug; and
(i) assaying cell status using said cell index values, wherein cell status refers to one or more selected from the group consisting of cell attachment or adhesion on the substrate including on the electrodes, the degree of cell spreading, the attachment area of the cell, the degree of tightness of cell attachment, cell morphology, cell growth or proliferation status; number of viable cells and/or dead cells in a well, cytoskeleton change and re-organization, and number of cells going through apoptosis and/or necrosis.
11. The method according to claim 10 , wherein cells are added to at least two wells of said device, each of which comprises an electrode array, and wherein said drug is added to the said at least two wells in different concentrations, further wherein impedance is monitored from said at least two wells.
12. The method according to claim 10 , wherein said monitoring impedance comprises monitoring impedances at three or more time points.
13. The method according to claim 12 , wherein at least three of said three or more time points are spaced at regular intervals.
14. The method according to claim 10 , wherein said cells are primary cells isolated from any species, or cells of cell lines.
15. The method according to claim 10 , wherein impedance is monitored at one frequency.
16. The method according to claim 10 , wherein impedance is monitored at multiple frequencies.
17. The method according to claim 10 , wherein impedance is monitored at multiple time points and at multiple frequencies at each of the time point.